research Cutaneous Adverse Events in Patients with Chronic Hepatitis C during Treatment with Directly Acting Antiviral Agents: A cohort study
34% of patients on hepatitis C treatment had reversible skin issues.
Search
for
Sort by
Research
30 / 1000+ results
research Alopecia areata after hepatitis C virus infection treatment: a case report
A patient developed hair loss after hepatitis C treatment with sofosbuvir and ribavirin.
research Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF ‐κB‐ and MAPK ‐ERK 1/2‐mediated COX ‐2 expression
Betulinic acid can help treat hepatitis C by stopping virus replication.
research Drug repositioning approach to target viral and host cells in terms of COVID-19 treatment: A review of in vivo experiments and clinical studies
Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
research Reporting on Adverse Clinical Events
Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
research Platelet-rich plasma for the treatment of androgenetic alopecia: A patient survey
PRP treatment for hair loss shows promise, with 58% of patients satisfied and most noticing improvement within 6 months.
research Placebo controlled clinical evaluation of a topical moisturizer formula containing phytol
The moisturizer with phytol improved skin texture and reduced fine wrinkles better than the moisturizer without it.
research PLAU and SerpinB2 role in apoptosis in leprosy
PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.
research Pityriasis rubra pilaris unveiling a case of a new onset hepatitis C infection
A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.
research Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
research Molecular mechanisms of viral oncogenesis in humans
Some viruses can cause cancer by changing cell processes and avoiding the immune system; vaccines and targeted treatments help reduce these cancers.
research Anti-Zika Activity of a Library of Synthetic Carbohydrate Receptors
Some synthetic carbohydrate receptors, especially compounds 3 and 15, show strong potential for treating Zika virus.
research Drug Repurposing Patent Applications July–September 2025
New drug uses show promise but need more research.
research Subject Index
research Frequency of Dyslipidemia in Patients with Lichen Planus: A Comparative Cross-Sectional Study
People with lichen planus are more likely to have abnormal blood fats than healthy people.
research Assessment of Dermatological Disorders with Chronic Hepatitis C Virus Infection
People with chronic Hepatitis C often have skin problems like itching and contact dermatitis, especially older individuals and women.
research Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies
Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
research Poster Abstracts
The model and estimator can predict drug exposure in kidney transplant patients well.
research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Hepatology highlights
Tenofovir is more effective than adefovir for resistant hepatitis B, Fibroscan is good for assessing liver damage, regulatory T cells may help hepatitis C persist, and other insights into liver health and disease were found.
research Advances in nucleoside monophosphate prodrugs as anti-HCV agents
New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
research Computational Screening of Repurposed Drugs Targeting Sars-Cov-2 Main Protease By Molecular Docking
Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
research A skin organoid-based infection platform identifies an inhibitor specific for HFMD
NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
research Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2
Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.
research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Golvatinib shows promise as a treatment for Omicron in elderly patients.
research Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects
Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
research Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.
research Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.